Generics
-
{
- All
- News
- Videos
-
Trump Imposes 100% Tariffs On Patented Drugs: Will It Impact India?
- Friday April 3, 2026
- World News | Edited by Srishti Kapoor
The bigger picture threatens a move away from established production hubs like India.
-
www.ndtv.com
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
- Monday March 30, 2026
- Health | Written by Sambhav Kumar
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
www.ndtv.com
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
- Monday March 30, 2026
- Health | Asian News International
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
www.ndtv.com
-
India Can Lead Global Probiotic Movement Using Traditional Diets, Says NITI Aayog's Rajiv Gauba
- Saturday March 28, 2026
- Health | Indo-Asian News Service
New Delhi, March 28 (IANS) India's rich heritage of fermented foods should be used to reverse the current shift toward ultra‑processed diets that threaten gut health and long‑term public health, Rajiv Gauba, Member, NITI Aayog, said at a probiotic sy
-
www.ndtv.com
-
Breakthrough: Peptide Pills Likely To Make Daily Insulin Injections Unnecessary Soon
- Wednesday March 25, 2026
- Health | Written by Shreya Goswami
Scientists have developed a peptide-based oral insulin delivery system that could replace daily injections. The innovation helps insulin survive digestion and enter the bloodstream, offering hope for easier diabetes management.
-
www.ndtv.com
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
- Wednesday March 25, 2026
- Health | Written by Varsha Vats
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
www.ndtv.com
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
- Tuesday March 24, 2026
- Health | Reported by Tanushka Dutta
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
www.ndtv.com
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
- Tuesday March 24, 2026
- Health | Indo-Asian News Service
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
www.ndtv.com
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
- Monday March 23, 2026
- Health | Written by Shreya Goswami
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
www.ndtv.com
-
Trump Imposes 100% Tariffs On Patented Drugs: Will It Impact India?
- Friday April 3, 2026
- World News | Edited by Srishti Kapoor
The bigger picture threatens a move away from established production hubs like India.
-
www.ndtv.com
-
GLP-1 Drugs In India: How To Spot Fakes Before It's Too Late
- Monday March 30, 2026
- Health | Written by Sambhav Kumar
Counterfeit GLP-1 drugs like semaglutide are rising in India amid growing demand and multiple cheaper versions entering the market.
-
www.ndtv.com
-
GLP-1 Should Not Be Used As A Quick Fix For Weight Loss And Diabetes Management, Warns Top Experts
- Monday March 30, 2026
- Health | Asian News International
Experts warn that GLP1 drugs like Ozempic and Wegovy aren't quick fixes. There are misuse risks that are involved as shortages, side effects, and weight regain are possible without medical supervision.
-
www.ndtv.com
-
India Can Lead Global Probiotic Movement Using Traditional Diets, Says NITI Aayog's Rajiv Gauba
- Saturday March 28, 2026
- Health | Indo-Asian News Service
New Delhi, March 28 (IANS) India's rich heritage of fermented foods should be used to reverse the current shift toward ultra‑processed diets that threaten gut health and long‑term public health, Rajiv Gauba, Member, NITI Aayog, said at a probiotic sy
-
www.ndtv.com
-
Breakthrough: Peptide Pills Likely To Make Daily Insulin Injections Unnecessary Soon
- Wednesday March 25, 2026
- Health | Written by Shreya Goswami
Scientists have developed a peptide-based oral insulin delivery system that could replace daily injections. The innovation helps insulin survive digestion and enter the bloodstream, offering hope for easier diabetes management.
-
www.ndtv.com
-
Affordable Weight Loss Drugs In India: How Cheap GLP-1s Will Affect Obesity Treatment
- Wednesday March 25, 2026
- Health | Written by Varsha Vats
Replacing traditional weight management methods with GLP-1 medications can be effective for some, but it's essential to approach this transition with caution.
-
www.ndtv.com
-
Drug Regulator Tightens Watch On GLP-1 Weight-Loss Drugs, Issues Notice
- Tuesday March 24, 2026
- Health | Reported by Tanushka Dutta
The Central Drugs Standard Control Organization, along with state regulators, has initiated targeted enforcement measures to curb malpractices and ensure ethical pharmaceutical practices in the supply chain.
-
www.ndtv.com
-
Safety Checks For New Generic Weight-Loss Drugs To Be Increased: Government
- Tuesday March 24, 2026
- Health | Indo-Asian News Service
New Delhi, March 24 (IANS) Amid serious concerns over recent introduction of multiple generic variants of GLP-1 based weight loss drugs in the Indian market, the government on Tuesday said it has intensified regulatory surveillance against the drug’s
-
www.ndtv.com
-
Tirzepatide And Semaglutide: Experts Explain New Diabetes, Obesity Drug Options
- Monday March 23, 2026
- Health | Written by Shreya Goswami
With semaglutide's patent expiry in India, cheaper generics may expand access to obesity and diabetes care. Experts weigh benefits, risks, and how tirzepatide compares as a next-generation dual-action therapy.
-
www.ndtv.com